An anti-MMR nanobody radiolabeled with 68Ga-NOTA has entered phase II clinical trials for imaging of MMR-expressing macrophages in head and neck squamous cell carcinoma as well as HL and NHL. Here, MRC1 is linked to Hodgkins lymphoma.